Item 7.01. Regulation FD Disclosure.

On January 10, 2020, Sorrento Therapeutics, Inc. (the "Company") issued a press release announcing that it received a non-binding proposal to acquire a majority or all of the issued and outstanding shares of the Company. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 and Exhibit 99.1 furnished as part of Item 9.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

© Edgar Online, source Glimpses